Short Communication Open Access
Volume 2 | Issue 1 | DOI: https://doi.org/10.46439/toxicology.2.008
Screening of medicinal drugs, drugs of abuse and alcohol in clinical and forensic specimens
Nicolas Donze1,*
- 1Clinical Chemist and Forensic Toxicologist, ICH, Valais Hospital, Switzerland
Corresponding Author
Nicolas Donze, nicolas.donze@me.com
Received Date: April 02, 2020
Accepted Date: June 03, 2020
Donze N. Screening of medicinal drugs, drugs of abuse and alcohol in clinical and forensic specimens. Arch Clin Toxicol. 2020; 2(1):13-14.
Copyright: © 2020 Donze N. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Predictors of relapse in alcohol use disorder: identifying individuals most vulnerable to relapse
Alcohol Use Disorder (AUD) is described as a chronic relapsing condition with definitive behavioral markers and is characterized by repeated drug intake despite severe negative consequences [1]. With 12-month prevalence rates at 14% and lifetime estimates of 29% [2], it is clear that AUD adversely and substantially affects individual and societal health [3]. Recognized clinically as affecting decision making, relationships, and neurological function [4]
A scoping review of outcome measures in ovarian cancer clinical trials
The incorporation of patient-reported outcomes (PROs) is essential for assessing whether a cancer treatment enhances overall patient well-being, beyond merely extending survival. This scoping review aimed to identify and analyze the use of PROs in ovarian cancer clinical trials.
Post-allogeneic stem cell transplant FLT3-targeted maintenance therapy: updates and considerations for clinical practice
Acute myeloid leukemia (AML) is characterized by multiple molecular and cytogenetic abnormalities, with increasing data to support clinical and prognostic implications to guide clinical decision making. One of the most well described mutations involves fms-like tyrosine kinase 3 (FLT3) that results in a constitutively active tyrosine kinase and is generally associated with poor prognosis involving shorter overall survival and higher rates of relapse.
Recent advances on visual cycle protein research and progress on clinical translation
Since the publication of our previous paper, Visual cycle proteins: Structure, function, and roles in human retinal disease (Tsin, et.al, JBC 293:13016, 2018) there has been significant progress on multiple topics discussed in this paper. In the present communication, we further explore research advances on two visual cycle proteins: DES1 and IRBP.
Vedolizumab has no effect on the course of non-alcoholic fatty liver disease: A retrospective cohort analysis
Background and Aim: Non-Alcoholic Fatty Liver Disease (NAFLD) is the commonest cause of chronic liver disease and is a leading cause of liver transplantation in the United States, with no approved medication to halt or reverse its progression. Recent animal-model prospective trial-suggested that drug Vedolizumab leads to improvement and reversal in the NAFLD-related metabolic derangements. Vedolizumab is an α4β7 integrin-inhibitor that is approved for use in IBD patients. Our study aims to understand Vedolizumab's impact on the course of NAFLD in inflammatory bowel disease (IBD) patients.